Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): A systematic review and meta-analysis

被引：27

作者：

Alajbegovic S. ^{[1
]}

Sanders J.W. ^{[2
]}

Atherly D.E. ^{[3
]}

Riddle M.S. ^{[2
]}

机构：

[1] School of Pharmacy, University of Washington, Seattle, WA

[2] Naval Medical Research Center, Silver Spring

[3] PATH, Seattle, WA

来源：

Systematic Reviews | / 1卷 / 1期

关键词：

Chemoprophylaxis; Fluoroquinolone; Meta-analysis; Rifaximin; Systematic review; Travelers' diarrhea;

D O I：

10.1186/2046-4053-1-39

中图分类号：

学科分类号：

摘要：

Background: Recent developments related to a safe and effective nonabsorbable antibiotic, rifaximin, and identification of postinfectious irritable bowel syndrome as a frequent sequela call for a need to reconsider the value of primary prevention of traveler's diarrhea (TD) with antibiotics.Methods: Randomized, placebo-controlled, double-blind studies evaluating the effectiveness and safety of rifaximin or a fluoroquinolone chemoprophylaxis against TD were pooled using a random effects model and assessed for heterogeneity.Results: The nine studies (four rifaximin and five fluoroquinolone) included resulted in pooled relative risk estimates of 0.33 (95% CI = 0.24-0.45, I2 = 3.1%) and 0.12 (95% CI = 0.07-0.20, I2 =0.0%), respectively. Similar rates of treatment emergent adverse events were found between antibiotic and placebo groups.Conclusions: This meta-analysis supports the effectiveness of antibiotics in preventing TD. However, further studies that include prevention of secondary chronic health outcomes among travelers to different geographic regions, and a formal risk-benefit analysis for antibiotic chemoprophylaxis, are needed. © 2012 Alajbegovic et al.; licensee BioMed Central Ltd.

引用

共 50 条

[11]

Thomson M.A., Booth I.W., Treatment of traveller's diarrhoea: economic aspects, Pharmacoeconomics, 9, pp. 382-391, (1996)

[12]

DuPont H.L., New insights and directions in travelers' diarrhea, Gastroenterol Clin North Am, 35, pp. 337-353, (2006)

[13]

Gorbach S.L., How to hit the runs for fifty million travelers at risk, Ann Intern Med, 142, pp. 861-862, (2005)

[14]

Hill D.R., Ericsson C.D., Pearson R.D., Keystone J.S., Freedman D.O., Kozarsky P.E., DuPont H.L., Bia F.J., Fischer P.R., Ryan E.T., The practice of travel medicine: guidelines by the Infectious Diseases Society of America, Clin Infect Dis, 43, pp. 1499-1539, (2006)

[15]

Halvorson H.A., Schlett C.D., Riddle M.S., Postinfectious irritable bowel syndrome: a meta-analysis, Am J Gastroenterol, 101, pp. 1894-1899, (2006)

[16]

Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 535-544, (2007)

[17]

Koo H.L., DuPont H.L., Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases, Curr Opin Gastroenterol, 26, pp. 17-25, (2009)

[18]

Koo H.L., DuPont H.L., Current and future developments in travelers' diarrhea therapy, Expert Rev Anti Infect Ther, 4, pp. 417-427, (2006)

[19]

Ericsson C.D., Travellers' diarrhoea, Int J Antimicrob Agents, 21, pp. 116-124, (2003)

[20]

DuPont H.L., Systematic review: prevention of travellers' diarrhoea, Aliment Pharmacol Ther, 27, pp. 741-751, (2008)

← 1 2 3 4 5 →